Please assess the completion status of the following clinical trial:

Trial Title: Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a man or a woman aged 18 to 55 years of age.~* Subject has chronic Hepatitis C~* Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period~Exclusion Criteria:~* Patient has evidence of advanced liver disease.~* Patient has human immunodeficiency virus (HIV)~* Patient has Hepatitis B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 25 mg b.i.d. MK7009
- 2 (Type: EXPERIMENTAL): 75 mg b.i.d. MK7009
- 3 (Type: EXPERIMENTAL): 250 mg b.i.d. MK7009
- 4 (Type: EXPERIMENTAL): 500 mg b.i.d. MK7009
- 5 (Type: EXPERIMENTAL): 700 mg b.i.d. MK7009
- 6 (Type: EXPERIMENTAL): 125 mg q.d. MK7009
- 7 (Type: EXPERIMENTAL): 600 mg q.d. MK7009
- 8 (Type: EXPERIMENTAL): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).